An update from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences Ltd announced an investor webinar to discuss their half-year report, progress on the ColoSTAT® test for colorectal cancer detection, and the integration of Genetype assets. The ColoSTAT® test, a simple blood-based test, aims to provide an alternative for those unable or unwilling to participate in current screening programs, potentially reducing mortality rates and healthcare costs. The acquisition of Genetype enhances Rhythm’s capabilities in genetic risk assessment, positioning the company to meet growing demand in preventative healthcare and precision medicine markets.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest possible stage, thereby reducing the global cancer burden. Rhythm collaborates with global partners to commercialize and distribute its solutions.
YTD Price Performance: 7.78%
Average Trading Volume: 378,475
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$28.14M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.